March 27, 2020
It’s been asked, “take the surge in equities with a grain of salt; how much real buying is behind this week moves, besides the bailout-induced short-covering”
Pre-open indications: Could be a ‘whack-a-stock” sort of day by the “machines” – the possible 8
I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
March 29, 2020
... will provide a test for investors by U.S. econ data being released.
Last week’s brief rebound was subsidized by government stimuli; what’s to support the next depth?
March 27, 2020
Another wipe-out re-tests the capacity to find a near-term bottom as we are not even close to the peak of ‘the infection curve”
Pre-open indications: 7 HITs <ALNY (-$3.01), IONS (-$0.34), CRSP (-$2.17), RARE (-$2.14), VCEL (-$0.65) RENE.L (-$0.00)> and 2 MISS <BSTG (+$0.50), SAGE (+$0.55)>
The week in review
Market talk, ideas and opinions; volatility sketches a contradictory picture of the short-term
March 29, 2020
... will provide a test for investors by U.S. econ data being released. Last week’s brief rebound was subsidized by government stimuli; what’s to support the next depth?
March 17, 2020
A scorecard of earnings of 35 covered companies (1 more - ATHX of 28 reporting) The current LPS (loss per share) or net income, cash positions i.e. "runways" - is a reflection of this universe's investing "status"
March 16, 2020
In all dose groups for adult patients (age 18 years or older), including the two higher dose groups, of its P1/2 clinical programs with achromatopsia due to mutation in the ACHM CNGB3 or ACHM CNGA3 genes. AGTC continues to enroll pediatric patients at the higher dose groups in both trials. The share price was up and the down -$0.17 BUY post disruption or give it a day, maybe 2
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
3 hours 1 min ago
RegMed Investors’ (RMi): the coming week ...
March 29, 2020
RegMed Investors’ (RMi): the coming week ...
March 27, 2020
RegMed Investors’ (RMi) closing bell: volatility strikes to the heart of cell/gene therapy sector and its sentiment indicator
March 27, 2020
RegMed Investors’ (RMi) pre-open: I’m worried about share pricing sustainability
March 26, 2020
RegMed Investors’ (RMi) pre-open: the stimulus is weighted by 3.28 M plus 1.8 M continuing unemployment claims
March 25, 2020
RegMed Investors’ (RMi) closing bell: stimulus inspires markets another 5% gain after Tuesday’s 11% incline
March 24, 2020
RegMed Investors’ (RMi) closing bell: cell and gene therapy recover as volume moves the ladder of inclines
March 24, 2020
RegMed Investors’ (RMi) pre-open: optimism inspires stability and possible some sustainability
March 23, 2020
RegMed Investors’ (RMi) closing bell: a distressed market influences the cell and gene therapy sector
March 23, 2020
RegMed Investors’ (RMi) pre-open: every indicator had been whacked to the downside as risk was defined by volatility
© 2020 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
